News for CVAC Stock

CureVac Announces Voting Results of General Meeting CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer CureVac to Present at the 12th International mRNA Health Conference CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer GSK and CureVac to Restructure Collaboration into New Licensing Agreement CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac Announces Voting Results of General Meeting CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK CureVac Appoints Thaminda Ramanayake as New Chief Business Officer CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology CureVac Announces Update to the Management Team CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board CureVac Announces Voting Results of General Meeting CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023 CureVac Announces Voting Results of Extraordinary General Meeting CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares CureVac Announces Proposed Public Offering of Common Shares CureVac Welcomes Myriam Mendila as New Chief Development Officer CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R) CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102 CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022 CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate CureVac Announces Voting Results of General Meeting CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022 CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study CureVac and GSK Enter into Pandemic Preparedness Contract with German Government CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R) CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry dievini and the Federal Republic of Germany Amend Shareholders’ Agreement Regarding Investments in CureVac N.V. CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology CureVac Streamlines European Network for mRNA Product Manufacturing CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60 CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R) CureVac Announces Voting Results of General Meeting CureVac Provides Supervisory Board Update CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV CureVac Appoints Klaus Edvardsen as Chief Development Officer CureVac: Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021 CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study CureVac Expands CVnCoV Covid-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV CureVac to Participate in Upcoming Investor Conferences CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV CureVac to Host Conference Call on COVID-19 Partnership Update on February 5, 2021 CureVac and UK Government to Collaborate on Development of Vaccines Against SARS-CoV-2 Variants CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma CureVac Announces Full Exercise of Underwriters' Option to Purchase Additional Common Shares CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares CureVac Announces Proposed Public Offering of Common Shares CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection CureVac : CureVac and Bayer Join Forces on COVID-19 Vaccine Candidate CVnCoV CureVac : CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020 CureVac to Report Third Quarter and First Nine Months 2020 Financial Results and Business Updates on November 30, 2020 CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV CureVac: CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research for Further COVID-19 Vaccine Development and Production Capacity Expansion